Motilal Oswal: Granules India A Quarter Of Record High Revenue Ebitda/PAT  
Medicinal tablets are arranged for a photograph in Mumbai. (Photographer: Dhiraj Singh/Bloomberg)

Motilal Oswal: Granules India A Quarter Of Record High Revenue Ebitda/PAT  

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy

Motilal Oswal Report

Post delivering spectacular earnings growth (76% YoY) in FY20, Granules India’s posted strong revenue/Ebitda/Profit after Tax in Q1 FY21. This was led by new launches in formulations (FDs) and better market penetration for intermediates.

We have raised our earning per share estimate by 12%/6% for FY21/22E to factor in (a) the increased FD business on account of Abbreviated New Drug Application (ANDA) launches in the U.S., (b) addition of new molecules in the Active Pharmaceutical Ingredient segment, (c) increased traction in existing products, and (d) improving profitability due to backward integration.

Click on the attachment to read the full report:

Motilal Oswal Granules India Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.